OPNT earnings

Indivior to acquire Opiant Pharmaceuticals for total consideration of $28.00 per share comprising of an upfront cash payment of $20.00 per share at closing plus contingent value rights (CVRs) worth up to $8.00 per share in cash, payable on achievement of certain net revenue thresholds for OPNT003Upfront payment represents a 111% premium to Opiant's closing share price of November 11, 2022, and 99% premium to Opiant's 30-day volume-weighted average share price; total consideration, inclusive of potential CVR payments, represents a premium of up to 195% and 178%, respectivelyAcquisition will expand Indivior's portfolio of addiction therapies and leverage its expertise and resources to maximize

Acquisition Strengthens and Extends Indivior's Position as a Leader in Addiction Treatment Opiant Pipeline Anchored by OPNT003, an Opioid Overdose Treatment with Clinically Demonstrated Characteristics Well-Suited to Confront Illicit Synthetic Opioids Like Fentanyl Potential Annual OPNT003 Net Revenue of $150 Million to $250 Million Acquisition Expected to be Accretive to Earnings after the Second Full Year of Launch of OPNT003 Indivior to Host Investor Call at 8:00 am U.S. Eastern Today RICHMOND, Va., Nov. 14, 2022 /PRNewswire/ -- Indivior PLC (LON: INDV) ("Indivior" or the "Company") and Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) ("Opiant") today announced that the companies have entered

SANTA MONICA, Calif., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. ("Opiant" or "Company") (NASDAQ:OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, today announced it will report its financial results for the third quarter ended September 30, 2022, after the financial markets close on Monday, November 14, 2022.   The Company's management team is scheduled to host a conference call and webcast at 4:30 p.m. ET on Monday, November 14, 2022. To access the call, please dial 1-877-407-0792 in the U.S. or 1-201-689-8263 outside the U.S. and provide the conference ID number: 13732765. To access the live webcast, please visit h

SANTA MONICA, Calif., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. ("Opiant") (NASDAQ:OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, today reported financial results for the three months and six months ended June 30, 2022, and provided a corporate update. Recent highlights include: Pipeline Update Rolling New Drug Application (NDA) submission for OPNT003, nasal nalmefene for opioid overdose remains on track, with completion expected in the second half of 2022Announced that the United States (U.S.) Patent and Trademark Office has issued a Notice of Allowance for U.S. patent with claims covering OPNT003 for opioid ove

SANTA MONICA, Calif., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. ("Opiant" or "Company") (NASDAQ:OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, today announced it will report its financial results for the second quarter ended June 30, 2022, after the financial markets close on Thursday, August 11, 2022.   The Company's management team is scheduled to host a conference call and webcast at 4:30 p.m. ET on Thursday, August 11, 2022. To access the call, please dial 1-877-407-0792 in the U.S. or 1-201-689-8263 outside the U.S. and provide the conference ID number: 13730815. To access the live webcast, please visit https

SANTA MONICA, Calif., May 10, 2022 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. ("Opiant") (NASDAQ:OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, today reported financial results for the three months ended March 31, 2022, and provided a corporate update. Recent highlights include: Finance Update Q1 revenues of $4.5 million; $2.2 million of revenue was attributable to the license agreement with Emergent BioSolutions, Inc. ("EBS") for the sale of NARCAN® Nasal Spray The royalty rate reduced in Q1 due to EBS applying the "Generic Reduction Clause" contained in the License Agreement Well capitalized, with approximately $50.8 million

SANTA MONICA, Calif., May 03, 2022 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. ("Opiant") (NASDAQ:OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, will report its financial results for the first quarter ended March 31, 2022, after the financial markets close on Tuesday, May 10, 2022.   The Company's management team is scheduled to host a conference call and webcast with slides at 4:30 p.m. ET on Tuesday, May 10, 2022. To access the call, please dial 1-877-407-0792 in the U.S. or 1-201-689-8263 outside the U.S. and provide the conference ID number: 13728852. To access the live webcast, please visit https://viavid.webcasts.com/starth

Study compared OPNT003, nasal nalmefene, with 4 mg nasal naloxone hydrochloride in reversing the respiratory depression produced by remifentanil, a synthetic opioidOPNT003 met the primary endpoint of non-inferiority, which was designed to assess whether nasal nalmefene performed as well or better than nasal naloxoneOPNT003 produced, at the primary end point of five minutes, a greater reversal in remifentanil-induced respiratory depression that was nearly twice that produced by nasal naloxone Completion of the PD study concludes the planned clinical development program for OPNT003; Company expects to complete an NDA filing for OPNT003 in the second half of 2022Company to discuss topline data

SANTA MONICA, Calif., March 15, 2022 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. ("Opiant") (NASDAQ:OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, today reported financial results for the three and twelve months ended December 31, 2021, and provided a corporate update. Recent highlights include: Finance Update Q4 revenues of $13.8 million, an increase of 39% compared to the same period in 2020 Exceeded full-year 2021 royalty revenue guidance of approximately $38 million with 2021 royalty revenue of approximately $41 million, a 49% increase over full-year 2020 Full-year net income of $3.0 millionWell capitalized, with approximate

SANTA MONICA, Calif., March 07, 2022 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. ("Opiant") (NASDAQ:OPNT), a specialty pharmaceutical company developing medicines for addictions and drug overdose, today announced it will report fourth quarter 2021 financial results and pipeline updates on Tuesday, March 15, 2022, after U.S. financial markets close. The Company's management team is scheduled to host a conference call and webcast at 4:30 p.m. ET on Tuesday, March 15, 2022. To access the call, please dial 1-877-407-0792 in the U.S., or 1-201-689-8263, outside the U.S. and provide the conference ID number: 13726931. To access the live webcast, please visit https://themediaframe.com/media

SANTA MONICA, Calif., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. ("Opiant") (NASDAQ:OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, today reported financial results for the three and nine months ended September 30, 2021, and provided a corporate update. Recent highlights include: Finance Update Q3 revenues of $16.3 million, a 79% increase over the same period in 2020, driven by NARCAN® Nasal Spray royalties Nine-month revenues of $34 million $50.3 million in cash, cash equivalents and marketable securities (as of September 30, 2021) Raises full-year 2021 revenue and cash guidance Royalty revenue from the sale o

SANTA MONICA, Calif., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. ("Opiant") (NASDAQ:OPNT), a specialty pharmaceutical company developing medicines for addictions and drug overdose, today announced it will report third quarter 2021 financial results and pipeline updates on Thursday, November 11, 2021, after U.S. financial markets close.  The Company's management team is scheduled to host a conference call and webcast at 4:30 p.m. ET on Thursday, November 11, 2021 to discuss the results and operational progress. To access the call, please dial 877-407-0792 in the U.S. or 201-689-8263 outside the U.S. and provide the conference ID number: 13723604. To access the live web

SANTA MONICA, Calif., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. ("Opiant") (NASDAQ:OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, today reported financial results for the three and six months ended June 30, 2021, and provided a corporate update. Recent highlights include: Pipeline and Corporate Update: OPNT003, nasal nalmefene, for opioid overdose: Completed confirmatory pharmacokinetic ("PK") study; data demonstrate rapid absorption and higher plasma concentrations versus a nalmefene intramuscular injection (p<0.0001)Data from Pharmacodynamic ("PD") anticipated later in the fourth quarter Increasing need for O

SANTA MONICA, Calif., July 22, 2021 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. ("Opiant") (NASDAQ:OPNT), a specialty pharmaceutical company developing medicines for addictions and drug overdose, today announced it will report its financial results for the second quarter ended June 30, 2021, after the financial markets close on Thursday, August 5, 2021. The Company's management team is scheduled to host a conference call and webcast at 4:30 p.m. ET on Thursday, August 5, 2021. To access the call, please dial 888-394-8218 in the U.S. or 323-794-2588 outside the U.S. and provide the conference ID number: 5960603. To access the live webcast, please visit http://public.viavid.com/index